FDA Clears Brella SweatControl Patch for Reduced Primary Axillary Hyperhidrosis
Patients can achieve reduced excessive underarm sweating after one in-office treatment.
Pembrolizumab Plus Lenvatinib Phase 3 Melanoma Trial Discontinued
Merck and Eisai discontinued the trial based on recommendations of an independent data monitoring committee.
First Dosing of Patient in Phase 2 Study Evaluating VP-315 for BCC
Verrica Pharmaceuticals is developing a potentially first-in-class oncolytic peptide.
The Mainstream Patient: April 10
This week's edition of the Mainstream Patient features stories about filler fatigue in 2023, the difference between RF microneedling and traditional microneedling, IPL hair removal devices, and more.
The Weekly Roundup: April 3-7
ICYMI, this week we had stories about the role of dermatology advanced practice providers in a clinic, denovoSkin for severe burns, spesolimab receiving a permanent J-code, and more.
Fatty Liver More Frequent in Alopecia Universalis and Patchy Alopecia Areata
Investigators examined the association between fatty liver and AA subtypes.
New Positive Phase 1 & 2 Results of DenovoSkin for Burns
Cutiss AG hopes to provide a safe and effective skin substitute for patients needing a skin graft after a severe burn.
The Role of Dermatology Advanced Practice Providers With Shanna Miranti, PA-C
Dermatology advanced practice providers work alongside physicians to improve patient care and access.
Cynthia Elliott, MD, Discusses Correlation Between Cosmetic Procedures and the COVID-19 Pandemic
Physicians across the US saw an uptick in cosmetic procedures after workers returned to offices.
Expert Treatment Tips You Don’t Want to Miss
From acne and psoriasis to skin cancer and hair loss, leaders in the industry share their quick tips that help save time.
The Mainstream Patient: April 3
This week's edition of the Mainstream Patient features stories about inclusivity in plastic surgery, the powerful benefits of glycerin, the best mineral sunscreens according to dermatologists, and more.
The Weekly Roundup: March 27-31
ICYMI, this week we had stories about session highlights from AAD 2023, FDA approvals of biosimilars and MCC treatments, the association between the Mediterranean diet and tumor response rates, and more.
What's Trending in Skin Care: March 2023
Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are popular for the month of March.
Q1 Accepted NDAs and sBLAs to Keep a Watchful Eye On
Three major NDAs and sBLAs were accepted by the FDA in Q1 of 2023, with PDUFA dates set in 2023 and 2024.
Adel Haque, MD, Provides His Best Advice for New Dermatologists
Learning how to prescribe biologics, talking to mentors, reviewing journals, and getting involved in clinical trials are all ways to boost your expertise.
Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD
Late-breaking positive phase 2a results were presented at AAD 2023.
The Weekly Roundup: March 20-24
Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma
The UK and Netherlands study assessed tumor response rates among 91 patients.
Lauren Miller, PA-C, Discusses SDPA and Updates in Dermatology
Miller shares upcoming news from the SDPA and important legislative updates for dermatology physician assistants.
Oleogel-S10 for Epidermolysis Bullosa Wounds Demonstrated Accelerated Healing
Phase 3 data of Oleogel-S10 was presented in a late-breaking session at AAD 2023 in New Orleans.
FDA Approves Retifanlimab-Dlwr for the Treatment of Metastatic or Recurrent Locally Advanced MCC
Incyte’s MCC indication is approved under accelerated approval based on tumor response rate and duration of response.
New TMB-001 Sub-Analysis Data Published in Clinical and Experimental Dermatology
Timber Pharmaceuticals is on its way to developing the first FDA-approved treatment for congenital ichthyosis subtypes.
FDA Approves Adalimumab-Adaz High-Concentration Formulation
Sandoz, a Novartis division, expects to launch the new adalimumab biosimilar on July 1, 2023.
Expert Tips on Alopecia Management From AAD 2023
Ronda Farah, MD, FAAD, shares her tips and tricks for treating varying types of alopecia.
Raj Chovatiya, MD, PhD, Discusses All Things Inflammatory Diseases at AAD 2023
With the recent therapeutic revolution, there has never been a better time to find the right treatment option for your patient suffering from inflammatory diseases.
Ruxolitinib Cream Maintains Disease and Symptom Control in Adults and Adolescents With AD
An AAD 2023 poster presentation reviewed the long-term safety periods of the TruE-AD1 and TRuE-AD2 trials.
RAPID3 Scores May Help Determine the Impact of DMARD Therapy on PsA Severity
A poster presentation from AAD 2023 explored RAPID3 scores to evaluate patient-reported outcomes in routine clinical practice therapy decisions regarding PsA.
Managing Office Politics and Clinical Negotiations With Neal Bhatia, MD
Bhatia shares key pearls from his sessions at AAD 2023 discussing office politics and how to run a clinical research unit.
Seth Matarasso, MD, Explains How to Respectfully Work With Frustrated Patients
According to his AAD 2023 session, Matarasso stresses it’s crucial to consider the type of patient you want as a loyal patient.
New Positive Topline Results of Tapinarof Cream for AD Down to 2 Years
Dermavant’s ADORING 2 phase 3 trial met all primary and secondary endpoints.